诺诚健华(上交所代码:688428;香港联交所代码:09969)今天宣布,公司自主研发的新型BCL2抑制剂mesutoclax(ICP-248)联合阿扎胞苷获国家药品监督管理局(NMPA)药品审评中心(CDE)批准开展临床研究,治疗髓系恶性肿瘤,包括但不限于骨髓增生异常综合征(MDS)等。ICP-248是一款新型口服高选择性BCL2抑制剂,BCL2是细胞凋亡通路的重要调控蛋白,其表达异常与多种恶性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.